In a bid to capitalize on the increasing prevalence of cannabis consumption in the US, pharmaceutical companies have introduced a new pill that claims to combat marijuana addiction. The experimental drug, AEF-0117, has shown promise in a small trial by reducing the addictive impact of THC, the primary psychoactive compound in cannabis. While the study published in the journal Nature Medicine may appear encouraging at first glance, a closer examination raises several concerns about the motives behind such pharmaceutical interventions.
Try Cornbread Hemp's new USDA-certified organic THC gummy. It's the first hemp THC gummy of…
Register to vote today to make your voice heard. The post Cannabis voter guide to…
We've all heard it before: smoke weed, and you'll become a lazy, unmotivated bum. The…
New THC+CBC Mood Mints from Rare Cannabinoid Company bring on mood-boosting effects quickly thanks to…
Pioneering research from Columbia University in New York suggests that psilocybin, the key component in…
A groundbreaking new study, funded by the Centers for Disease Control and Prevention, suggests exactly…